Literature DB >> 22481354

Cancer: Limitations of therapies exposed.

Oriol Casanovas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22481354     DOI： 10.1038/484044a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  18 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.

Authors:  Emmanuelle Charafe-Jauffret; Christophe Ginestier; Flora Iovino; Carole Tarpin; Mark Diebel; Benjamin Esterni; Gilles Houvenaeghel; Jean-Marc Extra; François Bertucci; Jocelyne Jacquemier; Luc Xerri; Gabriela Dontu; Giorgio Stassi; Yi Xiao; Sanford H Barsky; Daniel Birnbaum; Patrice Viens; Max S Wicha
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

3.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

Authors:  Herbert I Hurwitz; Louis Fehrenbacher; John D Hainsworth; William Heim; Jordan Berlin; Eric Holmgren; Julie Hambleton; William F Novotny; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

4.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

Review 5.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

6.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

Review 7.  Modes of resistance to anti-angiogenic therapy.

Authors:  Gabriele Bergers; Douglas Hanahan
Journal:  Nat Rev Cancer       Date:  2008-08       Impact factor: 60.716

8.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform.

Authors:  Andrea Casazza; Boaz Kigel; Federica Maione; Lorena Capparuccia; Ofra Kessler; Enrico Giraudo; Massimiliano Mazzone; Gera Neufeld; Luca Tamagnone
Journal:  EMBO Mol Med       Date:  2012-01-13       Impact factor: 12.137
View more
  15 in total

1.  Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells.

Authors:  Surya P Singh; Abhijeet Mishra; Ritis K Shyanti; Rana P Singh; Arbind Acharya
Journal:  Biol Trace Elem Res       Date:  2020-06-18       Impact factor: 3.738

2.  Scheduling of anticancer drugs: timing may be everything.

Authors:  Astrid A M Van der Veldt; Adriaan A Lammertsma; Egbert F Smit
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

3.  Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients.

Authors:  Ying-Jian Song; Li-Xin Wang; Yong-Qing Hong; Zheng-Hong Lu; Qiang Tong; Xiao-Zheng Fang; Juan Tan
Journal:  Tumour Biol       Date:  2015-11-11

4.  CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.

Authors:  Sukhbir Kaur; Tiffany Chang; Satya P Singh; Langston Lim; Poonam Mannan; Susan H Garfield; Michael L Pendrak; David R Soto-Pantoja; Avi Z Rosenberg; Shelly Jin; David D Roberts
Journal:  J Immunol       Date:  2014-09-08       Impact factor: 5.422

5.  BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.

Authors:  Bercin Kutluk Cenik; Katherine T Ostapoff; David E Gerber; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2013-05-31       Impact factor: 6.261

6.  Enhancement of recombinant human endostatin on the radiosensitivity of human pulmonary adenocarcinoma A549 cells and its mechanism.

Authors:  Xiao-dong Jiang; Yun Qiao; Peng Dai; Qin Chen; Jin Wu; Da-an Song; Shi-qiu Li
Journal:  J Biomed Biotechnol       Date:  2012-06-18

7.  Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype.

Authors:  Marta Larrayoz; Ruben Pio; María J Pajares; Isabel Zudaire; Daniel Ajona; Oriol Casanovas; Luis M Montuenga; Jackeline Agorreta
Journal:  EMBO Mol Med       Date:  2014-02-05       Impact factor: 12.137

8.  Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment.

Authors:  Ting Wang; Siwei Chen; Shihui Wang; Liang Shi; Chenggong Wang; Jingxin Zhang; Yanfeng Gao; Guodong Li; Yuanming Qi; Xiuli An; Lixiang Chen
Journal:  Oncotarget       Date:  2017-06-20

9.  Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [(11)C]docetaxel.

Authors:  Astrid A M van der Veldt; Egbert F Smit; Adriaan A Lammertsma
Journal:  Front Oncol       Date:  2013-08-13       Impact factor: 6.244

Review 10.  MicroRNAs in cancer metastasis and angiogenesis.

Authors:  Weiyang Lou; Jingxing Liu; Yanjia Gao; Guansheng Zhong; Danni Chen; Jiaying Shen; Chang Bao; Liang Xu; Jie Pan; Junchi Cheng; Bisha Ding; Weimin Fan
Journal:  Oncotarget       Date:  2017-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.